ARS-1630

ARS-1630

A649218-5mg

5mg

≥98%

-20°C储存

超低温冰袋运输

ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1. In Vitro KRAS G12C is recently identified to be potentially druggable by allele-specific covalent targeting of Cys-12 in vicinity to an inducible allosteric switch II pocket (S-IIP). Success of this approach requires active cycling of KRAS G12C between its active-GTP and inactive-GDP conformations as accessibility of the S-IIP is restricted only to the GDP-bound state. This strategy proves feasible for inhibiting mutant KRAS in vitro. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:KRAS(G12C)

ARS-1630 是 ARS-1620 的一种活性较低的对映体，是从专利 WO 2015054572 A1 中提取的一种新型突变 K-ras G12C 抑制剂。

1698055-86-5

C21H17ClF2N4O2

430.84 g/mol

C=CC(N1CCN(C2=C3C=C(Cl)[C@@]([C@@]4=C(O)C=CC=C4F)=C(F)C3=NC=N2)CC1)=O.[R]

DMSO : ≥ 100 mg/mL (232.10 mM)